The Supreme Court on May 18 declined to consider appeals by six pharmaceutical companies challenging the government’s ability to negotiate prescription drug prices for the Medicare program.
The decision effectively ends those lawsuits, all but guaranteeing that the Medicare Prescription Drug Price Negotiation Program, authorized by Congress in 2022, will continue.
